Thiazoles - Therapeutic use
Research News and Information

Monday, November 23, 2009

Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib.

29 Nov 2009 Tyrosine kinase inhibitors, such as imatinib, have dramatically improved the outcomes for patients with selected cancers. For imatinib, western blotting of phospho-CrkL was an insensitive, indirect, and descriptive method to determine drug efficacy. ... Read more...

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

13 Sep 2009 BACKGROUND: In patients with chronic-phase chronic myeloid leukemia (CP-CML), imatinib resistance is of increasing importance. Imatinib dose escalation was the main treatment option before dasatinib, which has 325-fold more potent inhibition than ... Read more...

Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.

30 Aug 2009 Despite advances in screening and treatment, colorectal cancer remains the second leading cause of cancer-related death in the United States. Cyclin-dependent kinases (Cdk) are deregulated in colorectal cancer by silencing of the Cdk inhibitor ... Read more...

Latest indexed articles for 'Thiazoles - Therapeutic use'

These are the very latest articles for this heading:

• Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. 29 Nov 2009
• Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. 29 Nov 2009
• Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression. 30 Oct 2009
• Trial renews interest in Chagas' disease. 29 Oct 2009
• Lasker Awards and papal portraiture: turning fields upside down. 29 Sep 2009
• Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). 13 Sep 2009
• Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032. 30 Aug 2009
• Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone--a claims database approach. 30 Aug 2009
• The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. 30 Aug 2009
• Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. 30 Aug 2009
• Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. 30 Aug 2009
• Bone hydatid disease refractory to nitazoxanide treatment. 30 Aug 2009
• FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. 24 Aug 2009
• Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. 23 Aug 2009
• Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. 2 Aug 2009
• Hepatitis C virus infection and immunomodulatory therapies. 30 Jul 2009
• Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. 30 Jul 2009
• P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. 28 Jul 2009
• Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. 28 Jul 2009
• Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. 13 Jul 2009

See a longer list of these articles.

Technical information about 'Thiazoles'

Registry Number: 0

Descriptor UI: D013844

Alternative terms: Thiazoles;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.886.675; D03.383.129.708;

Technical Notes: includes thiazolines, thiazolidines